Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
10.88
-0.12 (-1.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
June 30, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Analyst Ratings for Arcutis Biotherapeutics
June 28, 2023
Via
Benzinga
Analyst Expectations for Arcutis Biotherapeutics's Future
June 12, 2023
Via
Benzinga
Why Shares of Arcutis Biotherapeutics Jumped This Week
June 09, 2023
The stock got a push when a British medical journal posted trials information on the company's lead product.
Via
The Motley Fool
Arcutis to Present at Upcoming Investor Conference
June 06, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for Arcutis Biotherapeutics
May 17, 2023
Via
Benzinga
Arcutis Biotherapeutics: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
Where Arcutis Biotherapeutics Stands With Analysts
March 29, 2023
Via
Benzinga
Arcutis Biotherapeutics's Earnings Outlook
February 27, 2023
Via
Benzinga
7 Short-Interest Stocks to Target for Explosive Gains
May 18, 2023
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 10, 2023
Via
Benzinga
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
May 02, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Global Payments, MGM Resorts And 3 Stocks To Watch Heading Into Monday
May 01, 2023
With US stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older
April 28, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Report First Quarter Financial Results
April 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
April 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
April 05, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
March 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
March 09, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
February 21, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
February 08, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
January 17, 2023
Via
Benzinga
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
January 14, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
December 19, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
December 12, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
December 05, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
November 28, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.